Combination treatment may slow disease progression in advanced sarcoma

An oral combination treatment may prevent the progression of advanced leiomyosarcoma, one of the most common subtypes of soft tissue sarcoma, according to a recent study published in The Lancet Oncology. "These findings support the combination as a potential treatment option for patients with advanced leiomyosarcoma and provide a strong rationale for further study aimed at improving outcomes in this difficult-to-treat cancer," said Seth Pollack, MD, the Steven T. Rosen, MD, Professor of Cancer Biology and a co-author of the study.